- Trump: Obamacare Replacement Might Take a Year
- ACA Repeal Seen Thwarting State Addiction Efforts
- Delay of Final Rule on The Confidentiality of Alcohol and Drug Treatment Information
- $7M for Opioid Outreach Sites & $6M for Opioid Abuse Training
- New Fact Sheet: The Case for Medication-Assisted Treatment (MAT) from The Pews Charitable Trusts
- Yale Finding May Aid in Opioid Abuse Treatment
- Getting Patients Hooked on An Opioid Overdose Antidote, Then Raising the Price
- Social Media Linked to Rise in Prescription Drug Abuse
- Kratom: What We Know
- The US Is Opening Its First “Safe Injection Facility” For Heroin Addicts
- Dr. Jana Burson Blog: U-47700 – Also Known as Pink or Pinky
LINKS TO ADDITIONAL NATIONAL NEWS OF INTEREST
- Marijuana Compound Shows Some Potential for Treating Opioid Addiction- 2/2/17
- Dr. Jana Burson Blog: Trump and the Opioid Grants: What Will Happen Next? – 1/31/17
- Heroin-Opioid Addiction Epidemic: Americans Need Work On Drug Abuse Awareness, Study Says – 1/25/17
- Take Back Our Cities From Opioids – Educate local leaders on how to help communities recover from the drug epidemic – 1/25/17
- New From the ATTC – Shared Decision Making and Medication-Assisted Treatment: A Supportive Approach to Initiating and Sustaining Addiction Recovery – 1/17
“President Donald Trump walked back his recent vow that Obamacare would be replaced in short order, telling Fox News’ Bill O’Reilly that the process is “complicated” and “maybe it’ll take till sometime into next year.”
“It statutorily takes a while to get,” Trump said in a wide-ranging interview that aired Sunday during the Super Bowl pre-game show. “We’re going to be putting it in fairly soon, I think that yes I would like to say by the end of the year at least the rudiments, but we should have something within the year and the following year.”
Source: Politico.com – February 5, 2017
“In the three years since the Affordable Care Act took effect, its federally funded expansion of Medicaid to low-income adults has become the states’ most powerful weapon in the battle against the nation’s worsening opioid epidemic.
Now, as Congress and President Donald Trump debate potential replacements for the law, governors, health care professionals and advocates for the poor are cautioning that any cut in federal funding for addiction treatment could reverse much of the progress states have made.
The Affordable Care Act (ACA) offered states the ability for the first time to provide Medicaid coverage to adults without children, with the federal government paying most of the bill. That change, and the law’s mandate that all insurers cover addiction treatment at the same level as medical and surgical procedures, has allowed states to ensure that low-income people can get the care they need, said Linda Rosenberg, CEO of the National Council for Behavioral Health, which represents nonprofit addiction treatment organizations.”
Source: HuffingtonPost.com – February 6, 2017
“The administration of President Donald Trump has issued a memorandum delaying implementation of all new and pending federal regulations. This regulatory “freeze” impacts the recently-released Final Rule modernizing federal regulations that govern the confidentiality of substance use disorder patient records, and the Supplemental Notice of Proposed Rulemaking (“SNPRM”) seeking comment on additional proposed changes to those regulations. The Final Rule and SNPRM, which were released by the Substance Abuse and Mental Health Services Administration (“SAMHSA”) and formally published in the Federal Register on Jan. 18, 2017, update and propose additional changes to the confidentiality regulations found at 42 C.F.R. Part 2, which are often referred to as “Part 2.”
As a result of the regulatory “freeze,” the confidentiality Final Rule will not become effective until Mar. 20, 2017 at the earliest. It was originally scheduled to take effect on Feb. 17, 2017. Accordingly, the Legal Action Center (“LAC”)’s analysis of the Final Rule will not be released to stakeholders until more guidance is available from the Trump administration regarding when and how the Final Rule will take effect.”
Source: Legal Action Center – January 25, 2017
“Authorized through the 2016 Comprehensive Addiction and Recovery Act (CARA), millions in grants are available to states and local governments for opioid abuse outreach programs across six categories.
The Bureau of Justice Assistance (BJA) is seeking system-wide initiatives as well as innovative approaches to promote substance misuse treatment and recovery support. Local governments and other applicants should focus on comprehensive cross-system planning and collaboration among officials who work in law enforcement, pretrial services, the courts, probation and parole, child welfare, reentry, prescription drug monitoring programs, emergency medical services and health care providers, public health partners and agencies that provide substance misuse treatment and recovery support services.
Funding is also available to deliver training and technical assistance (TTA) to state and local criminal justice and substance abuse treatment agencies, prescription drug monitoring programs and partner agencies in sites selected.
Source: EfficientGov.com – February 1, 2017
The fact sheet addresses the effectiveness of MAT, treatment gaps, and closing the treatment gap.
A PDF of the fact sheet is available for download at: http://www.pewtrusts.org/~/media/assets/2017/02/thecasemedicationassistedtreatment.pdf
Also available is a fact sheet: Medication-Assisted Treatment Improves Outcomes for Patients With Opioid Use Disorder published in November 2016 available at: http://www.pewtrusts.org/en/research-and-analysis/fact-sheets/2016/11/medication-assisted-treatment-improves-outcomes-for-patients-with-opioid-use-disorder
Source: Pews Charitable Trusts – February 1, 2017
Categories: Addiction, Heroin, Medication-Assisted Treatment (MAT), Methadone, News Updates, Opioid Abuse/Addiction, Opioids, Prescription Drugs
Tags: Addiction, Buprenorphine, Methadone Treatment, Substance Abuse Treatment
“Researchers at Yale University have found a genetic variant that may make treatment of opioid addiction more effective.
According to a news release from Yale, the variant helped identify African Americans who might need higher doses of methadone — the most effective treatment for those dependent upon heroin or prescription painkillers. The authors said the discovery may allow doctors to more quickly identify patients who must receive higher doses of methadone.
The genetic variant identified among African-Americans is adjacent to the gene OPRM1, which encodes the main cell receptor targeted by opioids in the brain. The variant could be used as a biomarker, helping tailor treatment for African-Americans with an opioid use disorder, note the investigators.”
Source: StamfordAdvocate.com – January 24, 2017
First came Martin Shkreli, the brash young pharmaceutical entrepreneur who raised the price for an AIDS treatment by 5,000 percent. Then, Heather Bresch, the CEO of Mylan, who oversaw the price hike for its signature Epi-Pen to more than $600 for a twin-pack, though its active ingredient costs pennies by comparison.
Now a small Virginia company called Kaleo is joining their ranks. It makes an injector device that is suddenly in demand because of the nation’s epidemic use of opioids.
Called Evzio, it is used to deliver naloxone, a life-saving antidote to overdoses of opioids. More than 33,000 people are believed to have died from such overdoses in 2015. And as demand for Kaleo’s product has grown, the privately held firm has raised its twin-pack price to $4,500, from $690 in 2014.”
Source: Kaiser Health News – January 30, 2017
“A 2017 study revealed a correlation between the popularity of social media and the rise of non-medical prescription drug use. The plethora of online social media sites are incredibly prominent and influential platforms that can be as much a nuisance as they are an asset.
Research led by Sanna Ronka at the Department of Social Research at the University of Helsinki noted online drug forums — though filled with information from a variety of sources — are often misleading and can lead to drug abuse, overdose and other risky behaviors.
Ronka noted how the online and offline worlds have blended together; the transition between online and offline is more seamless and frequent than ever before. People rely heavily on the internet and tend to use social media as their primary source for information.
Popular online social activities usually involve exploring and discussing topics through personal experiences, professional research, and sometimes fabricated personal experiences in online communities called forums. With no regulations or filters, the accuracy of this information can be questionable. Ronka’s study followed the activity of a popular Finnish drug forum, “Dopeinfo,” which was established in 2005.”
The article published in The International Journal of Drug Policy can be accessed at: http://www.ijdp.org/article/S0955-3959(16)30280-8/fulltext
Source: AddictionNow.com – January 25, 2017
“The US Drug Enforcement Administration (DEA) recently declared that it will hold off on a previously announced ban of the herbal drug kratom, as there was a need for additional input regarding this decision from the public and the US Food and Drug Administration (FDA). In August 2016, the DEA had suggested that it planned to add the psychoactive compounds found in the herbal agent kratom to the list of Schedule I drugs banned under the Controlled Substances Act. This led to significant outrage and clamor from individuals who believe that the herbal supplement, which is derived from trees indigenous to Southeast Asia, can help individuals struggling with a number of different medical issues, including opioid addiction.
Since publishing that notice, the DEA has heard from many concerned members of the public challenging the Schedule I action and requesting that they strongly consider their comments. Many people reported how helpful this particular herbal remedy has been. A decision was made to hold off on imposing the ban on a temporary basis while the DEA awaits further analysis by the FDA. This does not mean, of course, that kratom will not eventually be made illegal.”
See related article: DEA Asked Public To Comment On Its Proposed Kratom Ban And 99 Percent Opposed It available at: http://www.huffingtonpost.com/entry/dea-kratom-ban-comments_us_589374f1e4b06f344e4074fa
Source: Medscape.com – January 23, 2017
“Seattle and King County, Washington will be the first places in the US to build so-called safe injection facilities for heroin users, Seattle mayor Ed Murray announced Friday, an effort to reduce an epidemic of deadly drug overdoses.
Long controversial, the facilities provide anyone who walks in with access to clean needles and space to inject drugs. Nurses are on hand monitoring the users, and, if an overdose occurs, can administer the reviving medication naloxone. The facilities also provide testing for HIV and hepatitis, as well as medical services.”
Source: BuzzFeed.com – January 28, 2017
“My patients are sometimes my best teachers, so when one of them mentioned a new opioid drug, I searched for information online. This new drug is called Pink, or Pinky, but its chemical name is U-47700.
This drug was first developed in the 1970’s by a scientist at Upjohn, a pharmaceutical company. This drug has never been studied in humans, but produces a strong opioid-type effect due to its action at the mu opioid receptor. It’s quite powerful, with estimated potency at seven or eight times that of morphine.
Last year, forty to eighty overdose deaths in the U.S. were attributed to this drug, depending on which source you read. As a man-made research drug, it was legal to obtain until late last year, when the DEA placed U-47700 on Schedule 1 status. This means it is no longer legal to buy online, and that it has a high potential for causing addiction and harm.”
Read more at: https://janaburson.wordpress.com/2017/02/05/u-47700/
Source: Dr. Jana Burson – February 5, 2017